Search clinical trials for: MK2461

Total 49 results

Merck Sharp & Dohme LLC

Completed

MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)

Neoplasm
Merck Sharp & Dohme LLC

Completed

MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)

Advanced Cancer
GlaxoSmithKline

Completed

Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers

HIV Infections | AIDS

Belgium
National Cancer Institute (NCI)

Recruiting

Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Recurrent Prostate Cancer | Prostate Cancer | PET Positive

United States
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)

Type 2 Diabetes Mellitus
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) (COMBO)

Advanced Solid Tumors

Spain, United States, Netherlands, Hungary, Italy, France, Belgium
Organon and Co

Completed

MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)

Migraine Headache
National Cancer Institute (NCI)

Recruiting

Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Urogenital Neoplasms | Bladder Cancer | Urothelial Cancer | Genitourinary Cancer | Urogenital Cancer

United States
National Cancer Institute (NCI)

Recruiting

T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy

Cancer Of Prostate

United States
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)

Diabetes Mellitus, Type 2
National Cancer Institute (NCI)

Terminated

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Metastatic Pancreatic Cancer | Histologically or Cytologically Confirmed Pancreatic Cancer | Unresectable or Borderline Resectable Pancreatic Cancer

United States
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

Diabetes Mellitus, Type II
Organon and Co

Completed

Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)

Migraine
Organon and Co

Completed

Treatment of Multiple Attacks of Acute Migraine (0462-025)

Migraine Headache
Organon and Co

Completed

MK0462 in Treatment of Migraine With Recurrence (MK0462-022)

Migraine Headache
GlaxoSmithKline

Completed

Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose

AIDS

Belgium
Organon and Co

Completed

Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)

Migraine
L'Oreal
Nestlé

Completed

Two Supplemented Against Skin Reactivity

Skin Sensitivity | Trans-epidermal Water Loss | Clinical Score | Assessment of Skin Moisturization Factors | Assessment of Serum Immune-regulatory Cytokine | Evaluation of Intestinal Flora Composition

France
Merck Sharp & Dohme LLC

Completed

Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)

Ocular Hypertension | Open-angle Glaucoma
Organon and Co

Completed

Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)

Migraine
Organon and Co

Completed

Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)

Migraine
Organon and Co

Completed

Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)

Migraine
Organon and Co

Completed

Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)

Migraine Disorders
Merck Sharp & Dohme LLC

Terminated

The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

Diabetes Mellitus Non-insulin-dependent
Merck Sharp & Dohme LLC

Completed

A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)

Liver Insufficiency
Organon and Co

Completed

Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)

Migraine Headache
Merck Sharp & Dohme LLC

Completed

Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

Renal Insufficiency | Hemodialysis
Urovant Sciences GmbH

Completed

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur)

Overactive Bladder

United States, Latvia, Hungary, Canada, Lithuania, Poland
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)

Diabetes Mellitus Non-insulin-dependent
Merck Sharp & Dohme LLC

Completed

A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)

Type 2 Diabetes Mellitus
National Cancer Institute (NCI)

Recruiting

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

Cancer Of Prostate | Prostate Neoplasms

United States
Merck Sharp & Dohme LLC

Completed

Sitagliptin Added-on to Insulin Study (0431-051)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)

Diabetes Mellitus, Type 2 | Chronic Renal Insufficiency
Merck Sharp & Dohme LLC

Completed

A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

Diabetes Mellitus, Type II
Merck Sharp & Dohme LLC

Completed

MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Type 2 Diabetes Mellitus
M.D. Anderson Cancer Center

Withdrawn

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Hormone Receptor Positive Breast Adenocarcinoma | Metastatic HER2 Negative Breast Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

Colorectal Neoplasms | Colorectal Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bile Duct Neoplasms | Metastatic Colorectal Cancer (Mcrc) | Intrahepatic Cholangiocarcinoma (Icc) | Intrahepatic Bile Duct Cancer

United States

3

Subscribe